Hellenic Institute for the Study of Sepsis

Name

Hellenic Institute for the Study of Sepsis

Legal name

Hellenic Institute for the Study of Sepsis

Website

https://sepsis.gr

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Sepsis clinical research
• Clinical trials
• Infectious disease research
• Precision medicine
• Biomarker-guided therapy

Headquarters

HQ city

Athens

HQ country

Greece

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Research Grants and Sponsorship: HISS operates as a non-profit research institute primarily funded through research grants, clinical trial sponsorships from pharmaceutical companies, and European Union research framework programs. Revenue comes from conducting sponsored clinical trials for companies like Sobi, Abbott, and others.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

HISS operates as a non-profit Clinical Research Organization (CRO) that designs, develops, implements, and analyzes complex clinical trials focused on sepsis, severe infections, and systemic inflammatory disorders. The institute conducts biomarker-guided immunotherapy trials, transcriptomic profiling, cytokine analysis, and Raman spectroscopy studies, and publishes national sepsis guidelines and postgraduate education programs. Revenue is generated through research grants and clinical trial sponsorships from pharmaceutical companies and European Union framework programs.

Product overview

Hellenic Institute for the Study of Sepsis (HISS) is a non-profit, non-commercial medical research organization founded in 2010, operating as a Clinical Research Organization (CRO) that designs, develops, implements, and analyzes complex clinical trials focused on sepsis and severe infections. The organization conducts its research through the Hellenic Sepsis Study Group and maintains a portfolio of completed and ongoing clinical studies including ACCESS (clarithromycin for CAP), SAVE-MORE (anakinra for COVID-19), EMBRACE (emapalumab for interferon-gamma-driven sepsis), REACT, PRECISION, POINT, HOMI-LUNG, and hidradenitis suppurativa studies (HIDRA03, HIDRA04). HISS also publishes Greek national sepsis guidelines and offers postgraduate education programs. The organization's research is funded by European projects including ImmunoSep, RISCinCOVID, EPIC-CROWN-2, Homi-LUNG, and POINT under Horizon 2020 grants.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Research Organization (CRO) Services HISS operates as a Clinical Research Organization providing design, development, implementation, and analysis of complex clinical trials for sepsis and severe infections, supporting investigators through the Hellenic Sepsis Study Group.
• ACCESS Study (Clarithromycin for Community-Acquired Pneumonia) A randomized clinical trial of oral clarithromycin in community-acquired pneumonia to attenuate inflammatory responses and improve outcomes. Phase III trial conducted in 18 Greek hospitals, demonstrating reduced mortality, respiratory failure progression, and secondary sepsis incidence.
• EMBRACE Study (Emapalumab/Gamifant) Phase 2a study evaluating emapalumab (Gamifant) in patients with interferon-gamma-driven sepsis (IDS). Trial enrolled 75 patients across 24 sites in Greece, showing 60% improvement in organ function versus 40% with placebo and 28-day mortality of 40% versus 52% in placebo arm.
• SAVE-MORE Study (suPAR-guided Anakinra) suPAR-guided anakinra treatment for COVID-19 pneumonia, validated for early management of respiratory failure. Double-blind randomized Phase III confirmatory trial conducted in 37 study sites in Greece and Italy with 606 patients enrolled.
• REACT Study Biomarker-guided early clarithromycin treatment to prevent sepsis progression in community-acquired pneumonia, building on findings from the ACCESS trial.
• PRECISION Study Safety and efficacy of anakinra treatment for patients with persistent respiratory symptoms post-acute COVID and immune system activation, targeting long-COVID syndrome.
• POINT Study Non-interventional prospective cross-sectional study of cardiovascular, pulmonary, and renal system non-communicable complications associated with post-acute phase of SARS-CoV-2 infection.
• HOMI-LUNG Study Non-interventional study investigating cardiovascular disease progression in survivors of community-acquired pneumonia and lung infection by SARS-CoV-2.
• HIDRA04 Study (Bermekimab/MABp1) Double-blind randomized clinical trial comparing MABp1 (bermekimab), a fully humanized antibody targeting interleukin-1alpha, over placebo for patients with severe hidradenitis suppurativa not eligible for adalimumab treatment.
• HIDRA03 Study (Anakinra) Double-blind randomized placebo-controlled clinical trial evaluating safety and efficacy of anakinra in patients with hidradenitis suppurativa. Phase II trial enrolled 20 participants across 2 sites in Greece.
• Greek Sepsis Guidelines National guidelines for sepsis definitions and management principles published by HISS, with versions available in English and Greek.
• Postgraduate Course in Sepsis and Systemic Inflammation Educational program in sepsis and systemic inflammation conducted by HISS, supporting continuing education for healthcare professionals.

Quantifiable outcome

• Clarithromycin reduced mortality from 17% to 8% in hospitalized CAP patients
• +5 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Swedish Orphan Biovitrum (Sobi)coreStrategic or Co-development Partner · 7 January 2026Collaboration on EMBRACE Phase 2a study evaluating emapalumab (Gamifant) in interferon-gamma-driven sepsis (IDS). The study enrolled 75 patients across 24 sites in Greece. Sobi and HISS are discussing next steps with regulatory authorities for a potential new indication for emapalumab.
• Greek Genome Center at BRFAAcoreStrategic or Co-development PartnerCollaboration with Greek Genome Center situated at the Biomedical Research Foundation Academy of Athens (BRFAA) for detailed studies of gene transcription and differential gene expression in ACCESS study.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• ICON plc: ICON is a top-tier global CRO offering comprehensive clinical research services across multiple therapeutic areas. Comparable to HISS as a contracted clinical trial operator, though ICON serves a broader portfolio and is significantly larger.
• IQVIA: IQVIA is the world's largest CRO, providing full-service Phase I-IV clinical trial design and execution across therapeutic areas. While HISS is a specialized sepsis-focused CRO, IQVIA represents the scaled, full-service incumbent against whose operational model HISS competes for sponsor relationships.
• Charles River Laboratories: Charles River provides preclinical and clinical research services, including safety assessment and clinical CRO services. Operates in adjacent clinical research service lines and competes with HISS for infectious disease and immunology trial sponsors.
• Medpace: Medpace is a mid-to-large CRO focused on therapeutically specialized clinical development across multiple indications. Its therapeutic specialization model and reputation for high-quality trial execution parallels HISS's therapeutic depth in sepsis.

Emerging players

• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with therapeutic focus areas including infectious disease and immunology. Comparable to HISS in clinical research service delivery, though more commercially oriented and broader in scope.
• INmune Bio: INmune Bio is a clinical-stage biotechnology company developing immunotherapies for inflammatory and neurodegenerative diseases. Comparable to HISS in biomarker-guided immunology research focus, though INmune Bio is a commercial drug developer rather than a research institute.
• CTI Clinical Trial and Consulting Services: CTI is a privately-held CRO with expertise in infectious disease, immunology, and hematology clinical trials. Comparable to HISS in therapeutic area focus and trial design capabilities, particularly for sepsis and inflammatory diseases.

Others

• Swedish Orphan Biovitrum (Sobi): Sobi is a Swedish biopharmaceutical company specializing in rare disease and immunology therapeutics. While a partner (not competitor) of HISS on EMBRACE, Sobi is relevant as the commercial sponsor developing emapalumab for sepsis indications, with overlapping research interests.
• Global Sepsis Alliance: Global Sepsis Alliance is a non-profit advocacy and research collaborative focused on sepsis. Comparable to HISS in sepsis-specific mission, though GSA is primarily an advocacy and awareness organization rather than a clinical trial operator.
• European Clinical Research Infrastructure Network (ECRIN): ECRIN is a non-profit organization supporting multinational clinical research in Europe. Similar in mission to HISS as a non-profit clinical research infrastructure entity, though ECRIN provides trial support across multiple indications rather than a single therapeutic area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/hiss_eims
• YouTubeyoutube.com/@HISS2011
• LinkedInlinkedin.com/company/hellenic-institute-for-the-study-of-sepsis

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hellenic Institute for the Study of Sepsis